Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

About HYMPAVZIAbout
HYMPAVZI
OverviewHYMPAVZI in Action
EfficacyEfficacyStudy DesignPrimary EndpointsSecondary EndpointsSafetyDosing & AdminDosing 

& Admin
DosingPen OverviewInjection Overview
Patient StoriesPatient
Stories
Meet a Real PatientIdentifying Potential Patients
ResourcesResourcesResourcesPatient Savings & Support
Full Prescribing InformationPatient InformationInstructions for UseIndication Patient Site
Meet PeterA HYMPAVZI patient since 2023

After starting treatment with HYMPAVZI in the clinical trials, Peter continues with once-weekly HYMPAVZI today.

“I think the once-a-week, subcutaneous dosing1 is definitely better for me... These innovations mean I can concentrate on what matters to me.”

—Peter, a real HYMPAVZI patient

Peter, 63, was diagnosed with severe hemophilia A at age 2

He enjoys golf, travel, and spending time with his wife, Joanna, and his dog, Stella

With HYMPAVZI, he appreciates the once-weekly dosing and minimal prep1

Video Transcript00:00
Peter
My name is Peter. I'm 63. I have hemophilia A, severe, and was diagnosed at the age of two.

00:09
Peter
It was pretty rough back at that point because there was no real treatment at all except for whole blood. So, we would drive almost 2 hours to Hamilton, for treatment.

00:20
Peter
And then, I believe, when I was about ten, we finally were able to take the product home with us. When you're doing a factor replacement, you need alcohol wipes, a tourniquet, the whole procedure. You have to mix the product together, as opposed to opening the pen. Nothing to mix. You take it out of the fridge, and it’s done for you.

00:43
Peter
The discussions with my doctor about the products were very to the point. They said that there was a trial, if I'd be interested in it. Fewer injections and it didn't involve intravenous, so that obviously caught my attention quickly.

1:01
Peter
I've been on it for at least a year, and it’s very straightforward and doesn’t consume much of my time.

1:10
Peter
I think the once-a-week dosing is definitely better for me.  I chose Sunday nights. I’m sitting on the couch maybe watching the TV or, or some football or something, and it's so much easier for me just to do it at that point.

1:28
Peter
We do like to go away quite often and again it was always packing up a special amount of the product that I would take with me. How much do I have to bring with me?

1:41
Peter
Going away to Europe, three weeks, three pens. It was nice not being tied down with all the other product. The innovations mean I can concentrate on the things that are important to me.

1:56
Peter
What I enjoy about golf is being able to do it physically and just the freedom of clearing your head from other obstacles, and I think that's why everybody does play the game.

2:13
Peter
Everything I've gone through, I think meeting my wife and being with her is the silver lining in my life.

2:21
Peter
She began quilting probably ten years ago, and then I would help her cut the fabric; we would work together like that.

2:34
Peter
I know that some people in studies had injection site reactions, headache, and itching, and that thromboembolic events are possible.

2:44
Peter
If somebody is considering HYMPAVZI, definitely talk to your doctor or to your hemophilia clinic. I'm certainly glad that I did.

2:52
Peter
Living with hemophilia I've had some rough patches. I've had some really incredible patches too. I managed to survive and thrive. Not just to exist, but to live, travel, see the world, have a partner.

3:17
Joanna
Is it nice?

3:18
Peter
Beautiful. Turned out very nice.

3:21
Joanna
Yeah, it's a beautiful color combination, right?

3:24
Peter
Ask your doctor about HYMPAVZI, and whether it would be right for you.

3:29
Voiceover
What is HYMPAVZI? 
HYMPAVZI is a prescription medicine used regularly to prevent or reduce the frequency of bleeding episodes in adults and children 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors. 

It is not known if HYMPAVZI is safe and effective in children younger than 12 years old. 

IMPORTANT SAFETY INFORMATION 
Important: Before you start using HYMPAVZI, it is very important to talk to your healthcare provider about using factor VIII and factor IX products
(products that help blood clot but work in a different way than HYMPAVZI). You may need to use factor VIII or factor IX medicines to treat episodes of breakthrough bleeding during treatment with HYMPAVZI. Carefully follow your healthcare provider’s instructions regarding when to use factor VIII or factor IX medicines and the prescribed dose during your treatment with HYMPAVZI. 

Before using HYMPAVZI, tell your healthcare provider about all of your medical conditions, including if you: 
  • have a planned surgery. Your healthcare provider may stop treatment with HYMPAVZI before your surgery. Talk to your healthcare provider about when to stop using HYMPAVZI and when to start it again if you have a planned surgery. 
  • have a severe short-term (acute) illness such as an infection or injury. 
  • have been told that you have a risk for blood clots. 
  • are pregnant or plan to become pregnant. HYMPAVZI may harm your unborn baby.

    Females who are able to become pregnant: 
    • Your healthcare provider will do a pregnancy test before you start your treatment with HYMPAVZI. 
    • You should use effective birth control (contraception) during treatment with HYMPAVZI and for at least 2 months after the last dose of HYMPAVZI. 
    • Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with HYMPAVZI. 
  • are breastfeeding or plan to breastfeed. It is not known if HYMPAVZI passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements. 

What are the possible side effects of HYMPAVZI?  
HYMPAVZI may cause serious side effects, including:
  • blood clots (thromboembolic events). HYMPAVZI may increase the risk for your blood to clot in blood vessels in your arm, leg, lung, or head which can be life-threatening. Blood clots have happened in people using HYMPAVZI. You may have an increased risk of blood clots if you have certain risk factors. Stop using HYMPAVZI and get medical help right away if you develop any of these signs or symptoms of blood clots: swelling or pain in arms or legs, redness or discoloration in your arms or legs, shortness of breath, pain in chest or upper back, fast heart rate, cough up blood, feel faint, headache, numbness in your face, eye pain or swelling, trouble seeing
  • allergic reactions. HYMPAVZI may cause allergic reactions, including rash and itching. Stop using HYMPAVZI and get medical help right away if you develop any of the following symptoms of a severe allergic reaction: swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness or fainting, fast heartbeat or pounding in your chest, sweating
The most common side effects of HYMPAVZI include: swelling, hardening, redness, bruising, and pain at injection site, headache, itching 

These are not all the possible side effects of HYMPAVZI. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. 

6:43
Peter
Check out HYMPAVZI.com to learn more.
Resources and support

Download educational resources that can support you and your patients

See the resources Loading
Identify potential patients

Explore ways to identify patients like Peter, who may benefit from HYMPAVZI

View patient profiles Loading
Reference:HYMPAVZI. Prescribing Information. Pfizer Inc.; 2025.
Patient Stories Resources and support

Download educational resources that can support you and your patients

See the resources Loading

HYMPAVZI is a registered trademark of Pfizer Inc.

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-HYM-USA-0601
Indications and usageHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.
Helix ISI Modal Headline Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Important Safety InformationVenous thrombotic events were reported in clinical studies with HYMPAVZI. Patients with independent risk factors for thromboembolic events may be at increased risk of thromboembolic events with use of HYMPAVZI. Consider the benefit and risk of using HYMPAVZI in patients with known risk factors for thromboembolism. Interrupt HYMPAVZI prophylaxis if diagnostic findings consistent with thromboembolism occur and manage as clinically indicated. If factor VIII or factor IX products are indicated in a patient receiving HYMPAVZI prophylaxis, the minimum effective dose of factor VIII or factor IX according to the product label is recommended.

HYMPAVZI may cause hypersensitivity reactions (including, but not limited to, urticaria and pruritus). If HYMPAVZI-treated patients develop a severe hypersensitivity reaction, advise patients to discontinue HYMPAVZI and seek immediate emergency treatment.

Based on its mechanism of action, HYMPAVZI may cause fetal harm when administered to a pregnant woman. Verify that females of reproductive potential are not pregnant prior to initiating HYMPAVZI. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with HYMPAVZI and for 2 months after the last dose.

A serious adverse reaction of peripheral swelling occurred in one patient. A serious adverse reaction of venous thrombosis occurred in 0.9% of patients (1/116) in the open-label extension study. Adverse reactions reported in ≥3% of patients treated with HYMPAVZI in clinical trials included injection site reaction (9% of patients); headache (7% of patients); pruritus (3% of patients).
IndicationsHYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
  • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
  • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.